As noted above, Levcromakalim, a Kir6.1/SUR2B channel opener, induces migraine headaches through the dilation of extracerebral arteries, suggesting that vascular KATP channel inhibitors might help treat migraines (Clement et al., 2023). This evidence concerns the gene KCNJ8 and migraine disorder.